Table 2.

PDGFRA rearrangement in unusual adult myeloid neoplasms

Author/journal	Disease	Treatment	Outcome
Tang et al., Acta Haematol 2012;128:83–87	Myeloproliferative neoplasm with eosinophilia	Imatinib – started at 400 mg daily and maintained at 100 mg daily	Complete hematologic and molecular remission at 12 months
Papanikolaou et al., Ann Hematol. 2012 May;91(5):785-7	Chronic eosinophilic leukemia with lytic bone lesions	Imatinib 200 mg daily; on progression, nilotinib 400 mg BID	Progressed to erythroblastoid blast crisis after 2 years on TKI
Sorour et al., Br J Haematol. 2009 Jul;146(2):225-7	Acute myeloid leukemia with eosinophilia	Imatinib with FLAG-Ida followed by matched unrelated allograft	Relapsed with Imatinib resistance; started on Dasatinib but died 15 months later
Lierman et al., Leukemia. 2009 May;23(5):845-51	Chronic eosinophilic leukemia blast crisis with Imatinib resistance	Sorafenib 400 mg BID	Hematologic response without molecular response for 3 months
Zota et al., J Clin Oncol. 2008 Apr 20;26(12):2040-1	Chronic myelomonocytic leukemia	Imatinib 400 mg BID	Resolution of eosinophilia without other hematologic response; progressed to extramedullary disease
Florian et al., Leuk Res. 2006 Sep;30(9):1201-5	Systemic mastocytosis with chronic eosinophilic leukemia	Incomplete response to hydroxyurea, corticosteroids and interferon-alpha; started on imatinib 100 mg in 2002	Long-term response to low-dose Imatinib (50-100 mg) after inadequate responses to previous therapies
Von Bubnoff et al., Leukemia. 2005 Feb;19(2):286-7	Chronic myeloproliferative disorder with eosinophilia	Imatinib 100-400 mg daily	Hematologic and symptomatic response for 6 months; progression to myeloid blasts crisis and malignant pleural effusion
Saflet et al., Genes Chromosomes Cancer 2004 May;40(1):44-50	Atypical chronic myeloid leukemia with t(4;22) leading to formation of BCR-PDGFRA fusion gene	Imatinib 100 mg daily	Complete hematologic response at 7-month follow up